FeNO Testing in Asthma Care

Although airway eosinophilic inflammation is a key characteristic of asthma, there are few methods available to measure it. This inflammation can be assessed by measuring eosinophils and eosinophilic cationic protein (ECP) in sputum or by measuring ECP in blood samples1. However, these methods are considered time-consuming, expensive, and not readily available.

For most asthma patients, airway inflammation is driven by an allergen-induced Th2 response2. Evidence from the literature suggests that fractional exhaled nitric oxide (FeNO) is a crucial biomarker for respiratory tract inflammation2. Elevated FeNO levels in asthma are thought to result from inducible NOS2 expression in the inflamed airways2. The NObreath® FeNO device provides a non-invasive and significantly more cost-effective alternative aid to diagnose asthma and assess airway eosinophilic inflammation.

This article delves into the challenges encountered within primary care and how the innovative technology of the NObreath® can assist. Additionally, the article discusses the transition of the use of the NObreath® from primary care environments to secondary care facilities.

Challenges in Primary Care

GPs often face restricted budgets due to resource allocation for population needs, and financial sustainability to stay within healthcare budgets and prevent overspending. Each patient appointment is typically limited to just 10 minutes.

Population needs

In the UK, approximately 5.4 million people, or about 8 in every 100 individuals, suffer from asthma3. The National Review of Asthma Deaths (NRAD) documented 195 asthma-related deaths among adults in 2013, highlighting preventable factors in 89 of the 195 deaths (46%), such as lack of specific asthma expertise (17%) and non-adherence to UK asthma guidelines (25%)4. FeNO testing is valuable in GP settings, as GPs often encounter a spectrum of asthma cases, from mild to severe. The NObreath® device facilitates rapid and reliable FeNO measurements, to allow GPs to make informed decisions and aid in identifying patients who do or do not require ongoing treatment5. This also reduces emergency visits and hospital admissions related to poorly controlled asthma.

Financial sustainability

One of the ongoing challenges in primary care is maintaining financial sustainability. The NObreath® FeNO device is cost-effective, with minimal ongoing costs. The device requires only one consumable- the NObreath® mouthpiece which has a long shelf life and an integrated infection control filter, effectively removes airborne bacteria (>99%) and viruses (>98%)6. The device also incurs low annual servicing costs and imposes no test limits*.

Time with patient

When a GP determines the need for a FeNO test using the NObreath®, there’s no warm-up time, and the device operates through a simple exhale-only technique with on-screen visual guidance. Patients receive instant results, eliminating wait times. Intended for adult and paediatric patients**, the NObreath® offers two test modes: a 10-second test mode for those up to 10 years old who cannot complete the 12-second test mode.  GPs can store up to 25 results in up to 50 patient profiles and view a graph of results. If a GP office possesses only one NObreath®, they benefit from the device size and portability, ensuring that healthcare providers can efficiently utilise the device wherever patient care demands.

Carol Stonham, a member of Bedfont® Scientific Limited Medical Advisory Board and policy lead for Policy Care Respiratory Society (PCRS), comments “The NObreath® is my preferred choice for primary care in managing asthma for many reasons. Primarily it suits the unpredictability of the volume of testing in primary care – none of the consumables or device needs to be used or lost in a short time frame. It is an intuitive machine which is easy to use and teaches patients of all ages.”

Primary Care to Secondary Care

Using the NObreath® device in primary care can reduce the number of inappropriate referrals to secondary care clinics. However, if a patient is referred to an asthma specialist in secondary care, the NObreath® FeNO device can aid in the diagnosis and management of asthma. The NObreath® helps differentiate between allergic (eosinophilic) and non-allergic asthma7. FeNO measurements show the patient’s response to the treatment, enabling accurate prescription of medication and safer, monitored adjustments. This helps patients understand their condition better by demonstrating how their FeNO levels correlate with their symptoms and treatment adherence. Measuring airway inflammation with the NObreath® can help monitor the effectiveness of medication and predict the risk of asthma attacks8***

Gold Standard FeNO Testing

FeNO testing is increasingly recognised as a valuable tool in the management of asthma, but what makes the NObreath® stand out from other FeNO devices on the market? Developed by Bedfont® in 2008, the NObreath® has over 15 years of clinical use and has been featured in numerous studies worldwide, contributing to the advancement of FeNO testing. Conforming to both the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines, the NObreath® is also one of three FeNO devices recommended by the National Institute for Health Care Excellence (NICE)9, an independent international organisation providing national guidance and advice to improve health and social care.

To find out how you can support your patients with FeNO testing in asthma care with the NObreath®, please visit: https://www.nobreathfeno.com/

*The NObreath® has been validated for up to 29,000 tests when used as instructed and properly maintained and serviced. The number of tests can be periodically checked within the settings of the device; when 29,000 tests are reached a service is recommended. Contact your local service centre.

**NObreath® can be used on paediatric and adult patients, provided they can follow test protocol. USA only: NObreath® can be used on patients 7+ years old.

***FeNO is not a definitive indication of asthma and should be used in conjunction with (but not limited to) spirometry, patient history, and symptoms.

References:

  1. Pizzichini E, Pizzichini MM, Efthimiadis A, Dolovich J, Hargreave FE. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. Journal of allergy and clinical immunology. 1997 Apr 1;99(4):539-44. DOI: 10.1016/S0091-6749(97)70082-4.
  2. Keller AC, Rodriguez D, Russo M. Nitric oxide paradox in asthma. Memórias do Instituto Oswaldo Cruz. 2005;100:19-23. PMID: 15962094 DOI: 10.1590/s0074-02762005000900005.
  3. What is Asthma? [Internet]. Asthma+ Lung UK. 2024. [Cited Monday 8th July 2024]. Available from: https://www.asthmaandlung.org.uk/conditions/asthma/what-asthma#:~:text=Asthma%20is%20a%20common%20condition,cough%20or%20a%20tight%20chest.
  4. Royal College of Physicians. Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Report. London, RCP; 2014.
  5. Taylor DR, Pijnenburg MW, Smith AD, Jongste J. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax. 2006 Sep 1;61(9):817-27. PMID: 16936238 PMCID: PMC2117092 DOI: 10.1136/thx.2005.056093.
  6. Public Health England. An Evaluation of Filtration Efficiencies Against Bacterial and Viral Aerosol Challenges. Salisbury: Public Health England; 2020.
  7. Ref: Coumou H, Bel EH. Improving the diagnosis of eosinophilic asthma. Expert review of respiratory medicine. 2016 Oct 2;10(10):1093-103. DOI: 10.1080/17476348.2017.1236688.
  8. Saito J, Gibeon D, Macedo P, Menzies-Gow A, Bhavsar PK, Chung KF. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. European Respiratory Journal. 2014 Feb 1;43(2):474-84. DOI: 10.1183/09031936.00048513.
  9. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath [Internet]. National Institute for Health and Care Excellence. 2014. [Cited Wednesday 10th July 2024]. Available from: https://www.nice.org.uk/guidance/dg12/chapter/5-Outcomes

A series of events and initiatives culminate in remarkable fundraising achievements by Med-Tech company Bedfont® and NewMed.

Bedfont® Scientific Ltd. world leaders in breath analysis, with over 47 years of expertise in the design and manufacture of medical breath analysis devices, welcomed the roaming Shaun the Sheep sculpture to its offices on Friday, 26th July, for the exciting announcement. Bedfont® teamed up with NewMed Ltd. earlier in the year to sponsor and support Heart of Kent Hospice and its various charity events throughout the year, and are extremely proud to have contributed to raising over £28,000.

Heart of Kent Hospice, based in Aylesford, is a charity with a passion for improving quality of life and provides specialist care and support to adults with terminal illnesses. Bedfont®, along with NewMed, have been actively involved in a variety of fundraising events for Heart of Kent Hospice, and have been engaging employees and the community to support this worthy cause.

In May, Bedfont® participated in the Bluebell Walk, following a picturesque walk through the North Downs and raised substantial funds through sponsorships and raffles. Bedfont® also proudly sponsored a beautiful Shaun the Sheep sculpture for the Hospice’s Shaun in the Heart of Kent art trail, the event not only highlights local artistry but also draws significant attention to the hospice’s mission. Additionally, Bedfont® took part in the Shaun the Sheep Selfie Challenge, capturing joyful moments and sharing them widely to further boost donations and awareness.

Jason Smith, Managing Director at Bedfont® Scientific Ltd., comments “At Bedfont®, we believe in the power of community and the importance of giving back. Our partnership with NewMed Ltd. and our ongoing support for the hospice, reflect our commitment to making a positive impact on the lives of those around us. We look forward to continuing our efforts and exploring new ways to support Heart of Kent Hospice in the future”

David Dadswell, Corporate Partnerships Manager at Heart of Kent Hospice, commented “Collaborating with the local business community plays a pivotal role in the Hospice’s strategy, and allows us to create increased awareness of the services we provide and supports our fundraising events to deliver the best experience for all those who participate. Both Bedfont® Scientific and NewMed fully immersed themselves into the recent Bluebell Walk as headline sponsors, exhibitors, and participants and through their efforts, we raised over £28,000. It’s the perfect partnership between organisations that have strong values around healthcare and a commitment to giving back to their local communities.

To find out more about Bedfont® and the continued efforts in supporting Heart of Kent Hospice, follow us on social media @BedfontLtd

Like any healthcare investment, consideration needs to be given when deciding which fractional exhaled nitric oxide (FeNO) device might best suit the clinical area in which it will be used. So, what would be sensible to consider when including FeNO devices for implementation into the respiratory pathway? And how does the NObreath® measure up?

External approval is an important factor in healthcare device purchase. It acts as an independent validation of quality and reliability. In England, approval from the National Institute of Health and Care Excellence (NICE) demonstrates that a device or medicine has been assessed by independent committees and has made evidence-based recommendations for the health and social care sector1. Technology appraisals2 assess the clinical and cost-effectiveness of health technology, including devices such as the FeNO device. As the technology market increases and additional devices are brought to market, it is important to investigate what external approval a device has received, and that it has undertaken an independent process before approval. The NObreath® has successfully undergone the required NICE technology appraisal.

Reassurance that tests performed are accurate, and repeatedly so, is vital in healthcare. The evidence for individual devices is reviewed as a part of the NICE technology appraisal. A device that is CE-marked also ensures that the manufacturer conforms to European standards for health, safety and environmental requirements.

A vital component in any healthcare system is the cost. As with many healthcare devices, this extends beyond the initial price tag. Is there an ongoing maintenance cost? What is the cost of the consumables such as mouthpieces required? Is there any potential for waste? Will the device offer longevity in a pathway if it is correctly maintained?

When considering cost, it is also worth considering the value of including the test and the potential price of not including FeNO in a respiratory pathway. Is there the potential for other costs to emerge without the test? Incorrect diagnosis resulting in lifelong unnecessary inhaled medication is seen in asthma3,with the associated costs to the patient and the healthcare system along with the additional burden a diagnosis of asthma can bring. Alternately, the cost and burden of a missed diagnosis can also occur leaving patients with untreated symptoms and the associated risk of asthma. Objective tests including FeNO are recommended4,5,6 in making an accurate diagnosis of asthma.

Tests that are simple to perform are more likely to be used in primary care where time is short. Recent research has found many competing priorities for services currently and the pressure on workforce training and capacity7 has impacted primary care’s ability to reinstate spirometry services. Despite funded training for spirometry in England, it has been slow to increase because of the complexity and time taken to achieve the required standard and registration. The requirement for competence in using a FeNO device is not as onerous, does not take long to complete and is free to complete in the UK. New technology should ideally be easy for patients to use, easy for competent healthcare professionals to teach to others who might undertake testing, and suitable for testing on a broad age range. FeNO testing meets all the criteria, it is a quick simple test that is relatively easy for all ages to perform with minimal coaching, and the test procedure is easy to teach to others.  

A device that is portable and can be moved between consulting rooms will increase its use and test availability for patients. This allows a FeNO test to be quickly and easily integrated into relevant primary care consultations.

One of the most impactful things that healthcare professionals are influenced by are guidelines. These may be international, national or local guidelines. FeNO has an identified place in the current guidelines 4,5,6. As guidelines progress to reflect the most current evidence, it is likely that FeNO testing as a part of the diagnostic process, and as a tool to monitor established asthma, will become more prominent.

Comparing the Bedfont® NObreath® FeNO device against these considerations, is it a good choice? The NObreath® has successfully been through the NICE technology appraisal so has demonstrated that it is a clinically effective device offering reliable repeatable testing and is cost-effective. The NObreath® is a non-invasive device with visual incentives to encourage patients of all ages to achieve optimal flow rate for testing. The test settings can be used for adults and children so is an all-age device. It is simple to explain and easy for patients to perform, taking a minimal amount of valuable consultation time. It is small, and easily transported. It requires annual servicing and minimal consumables and can be used as a functional device for many years.

Taking advantage of these features, some practices and primary care networks have taught all clinicians how to perform the test when the patient initially presents with a history and symptoms of asthma, so that treatment can begin without delay and the patient can be reviewed with steroid naive FeNO results as the national and international guidelines recommend.

References:

  1. National Institute for Health and Care Excellence (2024). Available from https://www.nice.org.uk/guidance [Last accessed 19.6.24]
  2. National Institute for Health and Care Excellence (2024). Available from https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance [Last accessed 19.6.24]
  3. Aaron SD, Vandemheem KL, FitzGerald JM, Ainslie M, Gupta S et al.: Canadian Respiratory Research Network. Re-evaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017;317:269-279
  4. British Thoracic Society (2019)Guidelines for the management of asthma. Available from https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/ [Last accessed 20.6.24]
  5. National Institute for health and Care Excellence (2017). Asthma: diagnosis, monitoring and chronic asthma management NG80. Available from https://www.nice.org.uk/guidance/ng80 [Last accessed 20.6.24]
  6. Global Initiative for Asthma (2024) Global Strategy for Asthma Management and Prevention. Available from https://ginasthma.org/2024-report/ [Last accessed 20.6.24]
  7. Doe G, JC Taylor SJC, Topalovic M, Russell R, Evans RA et al (2023) Spirometry services in England post-pandemic and the potential role of AI support software: a qualitative study of challenges and opportunities. British Journal of General Practice 2023;  73 (737): e915e923. DOI: https://doi.org/10.3399/BJGP.2022.068

Plastic Free July, a pivotal initiative of the Plastic Free Foundation, was launched in 2011 by Rebecca Prince-Ruiz. This global movement is dedicated to realising a world free of plastic waste. The staggering figure of 20 million metric tons of plastic litter that infiltrates our environment annually1 underscores the urgent need for collective action against this pervasive global issue.

Bedfont®, world leaders in breath analysis, is fully committed to reducing its impact on the environment. By working with employees, customers and suppliers, materials are sustainably sourced and, where possible, recyclable or biodegradable materials are used.

Plastic packaging can take hundreds to thousands of years to decompose, accumulating plastic waste in landfills and natural habitats and creating long-term environmental pollution.

Bedfont® are always taking steps to reduce plastic waste; a couple of examples are:

The iCOquit®: a personal carbon monoxide (CO) device which is used to help people quit smoking. Initially, the iCO™ released in 2015 came in plastic packaging. When the next generation, iCOquit®, was introduced in 2020, Bedfont® changed the packaging to an eco-friendly material that can be recycled.

Another significant stride in this direction is the transformation of the Steribreath™ mouthpiece. Initially made of polypropylene, this component was revamped in 2020 to the more sustainable Steribreath™ Eco version, made from and packaged in sustainably sourced and recyclable materials.

These steps are part of the broader Bedfont® Eco Resolution. By making these changes, Bedfont® is not only reducing plastic waste but also reinforcing its commitment to sustainability.

As we celebrate Plastic Free July, Bedfont® is dedicated to continuing efforts to reduce plastic usage, lower its carbon footprint, and innovate in ways that benefit both its distributors and the environment.

To keep up to date with the Bedfont® Eco Resolution make sure you follow our social channels.

1. ICUN, Issues Brief, Plastic Pollution. [cited on 19/6/24] Available from https://www.iucn.org/resources/issues-brief/plastic-pollution

To mark Love Your Lungs Week, Bedfont® Scientific Ltd. raises awareness of FeNO testing in asthma care.

Love Your Lungs Week is an annual event which takes place from 21st to 27th June. The event aims to raise lung health awareness and promote habits that support respiratory well-being. Bedfont®, world leaders in breath analysis have over 47 years of experience in designing and manufacturing of breath analysis devices. Through innovating breath analysis devices, Bedfont® look to improve patient care with devices like the NObreath®. The NObreath® is a Fractional Exhaled Nitric Oxide (FeNO) device, recommended by NICE for FeNO measurement in asthma care.

Asthma is a chronic respiratory condition where the airways become inflamed and narrowed, making breathing difficult. Sadly 1,261 people lost their lives from asthma in 20201, highlighting that asthma is a serious condition. Asthma is caused by a combination of genetic and environmental factors, and as there is no cure, treating and managing the condition is essential.

FeNO is produced naturally in the lungs and can be found in exhaled breath; measuring FeNO can help assess the level of inflammation in the lungs, aiding in the diagnosis and management of asthma.

Using a FeNO device such as the NObreath® is a quick and easy, non-invasive way to assess a patient’s FeNO level. The NObreath® is especially useful for managing asthma in patients who are known to have allergic triggers, as it specifically measures the type of inflammation most commonly associated with allergic asthma

Elevated FeNO levels can suggest eosinophilic inflammation, a common underlying cause in many asthma patients. By using the NObreath® to monitor these levels, healthcare providers can tailor treatment efficiently.

Jason Smith, Managing Director of Bedfont® says “At Bedfont®, we are committed to supporting initiatives that promote lung health. Love Your Lungs Week is an excellent opportunity to raise awareness about the importance of early diagnosis and proactive management of respiratory conditions. The NObreath® FeNO device not only aids in identifying airway inflammation but also assists in monitoring treatment efficacy, ensuring that patients receive the best possible care.”

The NObreath® is fairly priced and conforms to both ATS and ERS guidelines, allowing a future where everyone has access to instant, non-invasive, simple breath testing to aid in medical diagnosis.

To find out more about FeNO testing in asthma care, please visit our website to watch an insightful webinar hosted by Carol Stonham MBE earlier in the year, ‘How FeNO testing can empower and educate healthcare professionals and patients alike:’ www.bedfont.com

1. Public health profiles. Office for Health Improvement & Disparities. [cited on 1/5/24] Available from https://fingertips.phe.org.uk/search/asthma 

World Well-being Week is dedicated to raising awareness about the importance of well-being in various aspects of life, including physical, mental, and emotional health. This year it takes place from June 24th to June 30th.

According to a recent study in 2023, personal well-being has declined, with the COVID-19 pandemic having a significant impact. Average ratings of well-being in the UK have declined across all measures between March 2022 and March 2023, with 57.41% of adults reporting high levels of anxiety and 46.6% reporting low levels of happiness1.

During World Well-being Week, companies are encouraged to support their employee’s well-being through various activities and resources. Workplace stress and burnout can significantly impact employee productivity and job satisfaction. Reports have shown that companies prioritising well-being have happier and more engaged employees, increasing workplace productivity and reducing employee absences.

Bedfont® have their very own team of Well-being Warriors, ensuring employees can take part in activities designed to reduce stress and enhance the workplace environment. Bedfont® is fully committed to well-being in the office and strives to promote and maintain the mental health and well-being of all employees, proving this by being presented with the Platinum Business Award by Kent County Council in April 2023, the highest award possible for promoting a positive work environment, and a health work/life balance.

In 2023, Bedfont® also opened their very own well-being garden, in memory of 2 well loved members of staff. The vision behind the garden is to give staff a special space to be able to enjoy, collect their thoughts, and de-stress.

Earlier this year, the Bedfont® Well-being Warriors were in full force for Stress Awareness Month, which occurs annually in April. The Warriors organised a week of stress-busting activities for staff, which included a virtual coffee morning, a stress-busting activity – Pictionary, a Wednesday walk, a Bedfont® bar with a music Kahoot quiz, and a healthy lunch. Employees were encouraged to join the activities and everyone thoroughly enjoyed themselves.

With personal well-being declining, it’s important, now more than ever, to ensure everything is being done to improve employee well-being. Here are some examples of how Bedfont® has been working to improve morale and well-being:

Well-being Gifts: Sending well-being packages or gifts to employees, such as stress balls, herbal teas, or wellness journals, to encourage them to take time for self-care.

Team Building Activities: Organising team-building activities that promote collaboration and social-well-being. These could be anything from group problem-solving challenges to fun games or social events.

Relaxation Spaces: Establishing relaxation zones in the workplace where employees can take short breaks to de-stress. These could include comfortable seating, ambient music, and access to mindfulness or meditation apps.

Healthy Eating Day: Promoting nutrition by hosting a healthy eating day. This could involve a workshop on nutritional information, providing healthy meals or snacks, or even organising a cooking demonstration focusing on healthy recipes.

Follow us on social media to keep up with all the news and information on what Bedfont® is doing to improve employee well-being.

  1. Personal well-being in the UK: April 2022 to March 2023. [Cited on 8/5/24] Available from https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/bulletins/measuringnationalwellbeing/april2022tomarch2023#:~:text=Adults%20with%20%E2%80%9Cvery%20bad%E2%80%9D%20self,and%203.8%25%2C%20respectively

Love Your Lungs Week is a national awareness event which occurs annually in June, taking place from 21st June to 27th June 2024. Initiated by the British Lung Foundation, now known as Asthma and Lung UK, the event focuses on enhancing lung health and looks to raise awareness of a variety of respiratory conditions that affect lung health. One of these conditions is asthma, which is a chronic condition where the airways become inflamed and narrowed, making breathing difficult.

Symptoms of asthma include:

  • Coughing
  • Wheezing
  • Chest tightness
  • Shortness of breath

What causes asthma?

It is thought that asthma is caused by a combination of genetic and environmental factors; when exposed to various irritants and substances, it can trigger asthma symptoms. There are 2 types of asthma; allergy-induced asthma and non-allergy induced asthma. Both types can have different triggers and these can vary from person to person.

Allergy-induced asthma is the most common form and can be triggered by inhaling allergens. This
can lead to an immune response in the airways which causes the symptoms of asthma. Common
allergens include:

  • Pollen: From trees, grass and weeds.
  • Dust Mites: Tiny creatures that thrive in household dust.
  • Pet Fur: Shed by cats, dogs and other furry pets.
  • Mould: Fungai that can grow indoors or outdoors in moist environments.

If these allergens are inhaled by someone with allergy-induced asthma, an allergic reaction can take place that causes the airways to swell, narrow and produce excess mucus.

Non-allergy induced asthma does not depend on an allergic reaction and is often triggered by factors not relating to allergies.

These can include:

  • Respiratory Infections: Such as the common cold or influenza.
  • Exercise: Especially in cold or dry air.
  • Stress and Emotions: Intense emotions can lead to hyperventilation and tightness in the chest.
  • Airborne Irritants: Such as smoke, chemical fumes, strong odours, or pollutants.

These triggers can cause the airways to swell and narrow but do not involve an allergic response. Instead, they may involve different inflammatory responses or hypersensitivity of the airways.

What impact does asthma have?

Asthma can have a significant impact on people’s lives, affecting their physical health, mental well- being and quality of life. The condition imposes lifestyle limitations, with sufferers often avoiding activities that might trigger symptoms, along with the economic burden from continuous medical care and loss of productivity due to absences from work or school.

Unfortunately, asthma-related emergency admissions remain high at over 35,000 in both adults and
children in the UK1, and with 1,261 people sadly passing away in 20201, it is clear more needs to be
done to avoid these numbers increasing.

What about FeNO testing?

Fractional Exhaled Nitric Oxide (FeNO) is found in exhaled breath and can aid in the diagnosis and treatment of asthma. FeNO is naturally produced in the lungs through a complex biological process. The measurement of FeNO helps assess the level of inflammation in the lungs, aiding in the diagnosis and treatment of asthma. Using a FeNO device like the NObreath® is a quick and easy, non-invasive way to read a person’s FeNO level. FeNO testing is especially useful for managing asthma in patients who are known to have allergic triggers, as it specifically measures the type of inflammation most commonly associated with allergic asthma.

How does FeNO fit into asthma management?

  • Diagnosis: FeNO testing can help in diagnosing asthma in cases where typical diagnostic tests (like spirometry) might not be conclusive. Elevated FeNO levels can suggest eosinophilic inflammation, which is a common underlying cause in many asthma patients.
  • Monitoring: For ongoing asthma management, FeNO levels can provide insight into how well inflammation is being controlled through medication, particularly inhaled corticosteroids.
  • Monitoring FeNO can help in adjusting medications more precisely to reduce inflammation.
  • Predicting Exacerbations: High FeNO levels can indicate poorly controlled asthma and predict potential exacerbations. This can be particularly useful in managing patients who have periodic flare-ups, allowing for preventive adjustments in treatment.
  • Assessing Treatment Response: Regular FeNO testing can assess the effectiveness of current asthma treatment regimens. If FeNO levels remain high despite treatment, it might suggest the need for alternative therapies or more aggressive management.

With World Asthma Day just a little over a month ago now, this years theme “Asthma Education Empowers” aimed to highlight the importance of education in asthma diagnosis and treatment. It is clear that the innovative approaches to its management, including FeNO testing, have never been more essential.

Bedfont® Scientific Limited, are world leaders in breath analysis, with over 47 years of expertise and knowledge in designing and manufacturing breath analysis devices. They are committed to improving patient safety through innovating breath analysis devices, such as the NObreath®. The device is a portable handheld FeNO device, used by healthcare professionals to aid in the diagnosis and treatment of asthma.

Bedfont® hosted an insightful webinar which looked in depth at how FeNO testing can empower and educate healthcare professionals alike. To read the Bedfont® blog article on this subject, and to watch the webinar, please click here.

1. Public health profiles. Office for Health Improvement & Disparities. [cited on 7/5/24] Available from
https://fingertips.phe.org.uk/search/asthma

World No Tobacco Day, established in 1987 by the World Health Organization (WHO), aims to raise global awareness about the tobacco epidemic and the preventable illnesses and deaths it causes. With the 2024 annual theme ”Protecting children from tobacco industry interference,” Bedfont® hosted a discussion with Smokerlyzer® Medical Advisory Board members, Dr Amer Siddiq Amer Nordin and Dr Anne Yee, along with insights from Professor Christopher Bullen from the University of Auckland.

Dr Amer Siddiq Amer Nordin

Dr Anne Yee

The discussion covered some fascinating points, looking at where the world is currently with the efforts to reduce tobacco use, and the challenges being faced along the way. The conversation looked closely at New Zealand and Malaysia.

What is happening in New Zealand?

In New Zealand, there has been a considerable effort in research and policy-making to reduce the number of young smokers; this has resulted in a drop in smoking in young people to below 5%, which is the lowest it has ever been. Whilst this statistic should be celebrated, the challenge now being faced is the considerable increase in the number of young people taking up vaping, with the majority of these people having never smoked.

Chris goes on to say that “we shouldn’t be complacent with these numbers; things can change very quickly, and we could well see a surge in the uptake of smoking again in the future.” Although New Zealand is on top of the situation currently, things need to be monitored very closely to avoid an increase in smokers.

In New Zealand, just like the UK, the government brought in legislation that anyone born after January 1st 2009 cannot legally buy tobacco products. However, Professor Bullen comments that a new government was appointed in March this year, who swiftly revoked that legislation.

What is happening in Malaysia?

Sadly, smoking remains a significant public health issue in Malaysia. However, the National Health & Morbidity Report did show a decline in cigarette use in 13-17 years-olds, dropping from 13.8% in 2017 to 6.2% in 2022. Showing a massive decrease in smoking in this age group is positive, yet, the same report did show an increase in e-cigarette and vape use in the same age group, increasing from 9.8% in 2017 to 14.9% in 2022. However, 10.8% of adolescent males were still smoking cigarettes in 2022 compared to 1.7% of adolescent females1; it seems that smoking is still a global issue.

Should we be concerned?

Tobacco companies are always looking for ways to increase smoking; if they are not successful, they are looking to push other products into the market, particularly in countries where the regulatory environment is weak. Dr Anne Yee comments that in Malaysia, vapes are being sold and positioned with snacks and sweets, making smoking and vaping seem more acceptable.

What is being done to reduce the number of people smoking?

In Malaysia, they introduced the Control of Tobacco Products Regulations under the Food Act of 1983 in 2004. These regulations included:

  • Advertising bans
  • Graphic health warnings
  • Restriction on sales to minors.

The Control of Smoking Products for Public Health Act 2024 has been published but is not yet operational in Malaysia, meaning sales of nicotine vapes are still available to minors. Dr Anne Yee fears Malaysia is falling behind in regulating vaping and innovative tobacco products and tobacco companies are seeing this as their way in.

Malaysia has implemented several measures to reduce smoking, such as:

  • Tak Nak, the anti-smoking campaign: The campaign was started to create awareness to encourage people to quit smoking and also discourage non-smokers from starting.
  • Introducing an anti-smoking program in the school curriculum: The program aims to educate and prevent young people from taking up smoking.
  • Quit Smoking Clinics: Set up across the country to offer counselling and nicotine replacement therapy.

Is branding an issue?

With some brands believed to be healthier than others branding is an issue. Like the UK, New Zealand introduced plain packaging and health warning labels on cigarette boxes, whereas Malaysia hasn’t been successful with this just yet.

What can we do to assist young people who want to quit smoking?

Unfortunately, there is not much evidence on which methods are best for adolescents to give up smoking, but in New Zealand, it has been suggested that text messaging has helped this age group. It is also thought that driving the price of tobacco up will discourage younger people to start smoking as they cannot afford it.

With everything discussed, it can be quite daunting when considering all the challenges faced in trying to reduce tobacco use. Nevertheless, we should celebrate how far the world has come in reducing smoking globally, and whilst vaping is rapidly increasing, smoking combustible tobacco is currently considered more dangerous. The world should continue efforts, hoping for a healthier population and a smoke-free future.

To watch the discussion in full visit our YouTube channel https://www.youtube.com/watchv=NeWDIAb9JGM&t=15s


1. NHMS Survey: Among Malaysian Teens, Smoking Rate Falls But Vaping Prevalence Rises To 15%.
CodeBlue. May 2023. [cited on 30/05/24]

Available from:
https://codeblue.galencentre.org/2023/05/25/nhms-survey-among-malaysian-teens-smoking-rate-
falls-but-vaping-prevalence-rises-to-15pc/#:~:text=The%20NHMS%20survey%20shows%20that,per
%20cent%20of%20adolescent%20females.

: The campaign was started to create awareness toencourage people to quit smoking and also discourage non-smokers from starting. Introducing an anti-smoking program in the school curriculum: The program aims toeducate and prevent young people from taking up smoking. Quit Smoking Clinics: Set up across the country to offer counselling and nicotinereplacement therapy.

World No Tobacco Day was created in 1987 by the World Health Organization (WHO) to draw worldwide attention to the global tobacco epidemic and the preventable death and disease it causes. Occurring annually, the day is marked by a different theme that aims to highlight a specific aspect of tobacco control.

What effect does tobacco use have on the world?

Killing over 8 million people a year, the tobacco epidemic is one of the biggest public health threats the world has ever faced. This includes an estimated 1.3 million non-smokers who are exposed to second-hand smoke1. Smoking has a profound impact on people’s health, affecting nearly every organ of the body and leading to a variety of diseases.

Tobacco use has a significant impact on healthcare costs and resources; some examples are:

  • Increased Healthcare Costs: Tobacco use is one of the leading causes of preventable diseases, including cardiovascular diseases, lung disorders, and various forms of cancer. Treating these conditions incurs substantial costs to healthcare systems.
  • Resource Allocation: The high prevalence of tobacco-related health issues demands significant healthcare resources, including hospital beds, medications, and medica personnel. This allocation of resources can strain healthcare systems, especially in regions with limited medical infrastructure.
  • Impact on non-smokers: Tobacco use also impacts non-smokers through exposure to second-hand smoke, leading to health conditions like respiratory infections, heart disease, and lung cancer. This increases the number of patients seeking medical help for tobacco-related conditions who themselves do not use tobacco.

How can the Smokerlyzer® range can help?

Bedfont® Scientific Limited manufactures the Smokerlyzer® range of carbon monoxide (CO) devices, used to aid in smoking cessation. The Smokerlyzer® range comprises of the Micro+™, piCObaby™, piCO™, and remote monitoring device iCOquit®, to help people stop smoking, one breath at a time.

The Bedfont® Smokerlyzer® range of CO devices works by measuring CO levels in a person’s exhaled breath, which can be used to determine a person’s smoking status. For smokers trying to quit, this quick, easy and non-invasive method of CO monitoring can offer instant insights on their quit progress and the colourful traffic-light system has proven to be an effective motivational tool to encourage them to quit.

Smokers can also monitor their progress remotely at home using the iCOquit®. This small, portable Bluetooth® CO device, when used alongside the free iCOquit® app, can provide instant results that can be shared remotely with smoking cessation advisors. Thanks to this innovative technology, stop- smoking services are even more accessible than before, helping the world work towards a smoke- free future.

Micro+™: One CO device for all your smoking cessation needs.


piCObaby™: CO monitoring for maternity made easy.


piCO™: CO monitoring made easy.


iCOquit®: Your personal CO device, to help you quit smoking, one breath at
a time.

Using a CO device to assist with quitting strongly supports the improvement of end results. A study by Beard and West (2012), on the effectiveness of personal carbon monoxide monitoring, found that out of 10 smokers, “7 of the smokers reported that they felt as though the monitors had reduced their cigarette consumption… 6 smokers reported a lower nicotine dependency relative to baseline. Over the 6 weeks there appeared to be a significant decline in the number of cigarettes smoked per day2”.

With more people than ever before having access to no smoking services, the Smokerlyzer® can help people quit, significantly reducing the financial and resource burden on healthcare systems caused by smoking-related diseases. Furthermore, with a lower prevalence of smoking, there will be a reduction in exposure to second-hand smoke; ultimately, this will contribute to solidifying a smoke- free future.

It’s clear that the fight against tobacco use is not just about discouraging a harmful habit but about safeguarding the future of public health globally. Let’s use this day to commit to reducing tobacco consumption in all forms, empower individuals to lead healthier lives and continue the momentum towards a world where tobacco no longer overshadows health and well-being.

If you are thinking about quitting smoking or struggling with your attempt, please visit the NHS quit
smoking page by clicking here.

To find out more about how the Smokerlyzer® range can help aid in smoking cessation, please click
here.


1. World Health Organization. [cited on 2/5/24] Available from https://www.who.int/news-room/fact-sheets/detail/tobacco

2. Pilot Study of the Use of Personal Carbon Monoxide Monitoring to Achieve Radical Smoking Reduction. Journal of Smoking Cessation. Emma Beard and Robert West (2012). [cited on 31/5/24] Available from https://web.archive.org/web/20180721211143id_/https://www.cambridge.org/core/services/aop-cambridge-core/content/view/0BAC2289E42E9C31C892D54BF7980237/S1834261212000011a.pdf/div-class-title-pilot-study-of-the-use-of-personal-carbon-monoxide-monitoring-to-achieve-radical-smoking-reduction-div.pdf

Back to top